Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?The Motley Fool • 07/01/24
Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes AssociationPRNewsWire • 06/24/24
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall StreetThe Motley Fool • 06/17/24
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor EnthusiasmInvestorPlace • 06/08/24
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease DrugInvestors Business Daily • 06/04/24
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)PRNewsWire • 06/04/24
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.The Motley Fool • 06/03/24
Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market TodayZacks Investment Research • 05/31/24